Thermal Ablation Versus Parathyroidectomy for Primary Hyperparathyroidism

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese PLA General Hospital

About this trial

This study is a prospective, multicenter study designed to compare the efficacy and safety of surgical treatment versus ablation therapy (including radiofrequency ablation and microwave ablation) for patients with primary hyperparathyroidism (PHPT). The study will assess the impact of both treatment modalities on serum parathyroid hormone (iPTH) and calcium levels, clinical symptom improvement, bone mineral density enhancement, reduction in the incidence of urinary system stones, and postoperative complication rates. While surgical treatment has been the standard of care for PHPT, offering definitive cure, it carries inherent surgical risks and complications. Ablation therapy, as a minimally invasive approach, presents a novel alternative with reduced trauma and fewer complications. The outcomes of this study will inform clinical decision-making and potentially optimize treatment strategies for patients with PHPT.

Eligibility criteria

Qualifiers

Symptomatic patients with primary hyperparathyroidism, such as those with symptoms in any system including the kidneys, bones, gastrointestinal tract, psychoneurological system, or those with atypical symptoms such as muscle weakness, dysfunction, and sleep disorders.

Imaging examination shows that at least one parathyroid gland is enlarged.

Disqualifiers

diagnosis of secondary or tertiary HPT

severe coagulation disorder

severe cardiopulmonary insufficiency

Trial design

Treatments tested in this trial

  • Thermal ablation
  • Parathyroidectomy

Treatment groups

520 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators